Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 3Phase 3 1

Status

Unknown 1Terminated 1Recruiting 1

Sponsor Class

NIH 3INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2Endocrine 1CNS 1

Conditions

Neoplasms 1522Carcinoma, Non-Small-Cell Lung 757Breast Neoplasms 572Neoplasm Metastasis 531Colorectal Neoplasms 447Melanoma 391Leukemia, Myeloid, Acute 372Multiple Myeloma 364Ovarian Neoplasms 354Recurrence 336Lymphoma 334Advanced Solid Tumors 325Lymphoma, Non-Hodgkin 315Prostatic Neoplasms 300Pancreatic Neoplasms 285Advanced Solid Tumor 240Stomach Neoplasms 233Carcinoma, Renal Cell 226Squamous Cell Carcinoma of Head and Neck 211Lung Neoplasms 210Solid Tumor 204Leukemia, Lymphocytic, Chronic, B-Cell 198Triple Negative Breast Neoplasms 184Solid Tumors 183Carcinoma, Hepatocellular 165Hematologic Neoplasms 155Head and Neck Neoplasms 153Lymphoma, Large B-Cell, Diffuse 148Lymphoma, Follicular 146Glioblastoma 145

Interventions

spartalizumab 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × von Hippel-Lindau Disease × Clear all
NCT04895748 2026-03-03

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

Novartis

Phase 1 Terminated
40 enrolled
CNSEndocrineGenitourinary

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell, von Hippel-Lindau Disease, Paraganglioma, Pheochromocytoma

NCT06553339 2024-08-14

A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 1 Recruiting
60 enrolled

von Hippel-Lindau Disease, Neuroectodermal Tumors, Primitive

NCT05843305 2023-05-06

A Study of BPI-452080 in Subjects With Solid Tumors

Betta Pharmaceuticals Co., Ltd.

Phase 1 Unknown
87 enrolled
Genitourinary

Carcinoma, Renal Cell, von Hippel-Lindau Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡